Clinical Trial Update: Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessed the combination of Herceptin (trastuzumab) and bevacizumab for HER2-positive metastatic breast cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Translational Oncology Research International | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED